Clik here to view.
JINS MEME API仕様を公開、開発者向けフェーズ本格始動
ラスベガス （ビジネスワイヤ） — 株式会社ジェイアイエヌ（東京本社：東京都千代田区、代表取締役社長：田中仁）は、2015年秋発売予定のセンシング・アイウエア「JINS MEME（ジンズ ミーム）」のアプリケーション開発者向けキットを配布するアイデアコンテスト「JINS MEME DEVELOPER IDEA PITCH CONTEST (ジンズ ミーム デベロッパー アイデア ピッチ...
View ArticleClik here to view.
JINS Opens API Specification for JINS MEME Smart Eyewear; Launches Idea Pitch...
LAS VEGAS JINS Co.,Ltd. (HQ: Chiyoda-ku, Tokyo: Hitoshi Tanaka, President) announced today that it will officially open the API specification for its groundbreaking JINS MEME smart eyewear to the...
View ArticleClik here to view.
Allegro Ophthalmics and Hanmi Pharmaceutical Announce Strategic Investment...
SAN JUAN CAPISTRANO, Calif. & SEOUL, South Korea Allegro Ophthalmics, LLC, and Hanmi Pharmaceutical Co., Ltd. today announced that they have entered into a license agreement for Luminate®...
View ArticleClik here to view.
Hoya Announces Third Quarter Financial Results
TOKYO Hoya Corporation (TOKYO:7741) today announced financial results for the third quarter ended December 31, 2014. During the quarter, revenues increased 16.9% to 128,206 million yen, and profit...
View ArticleClik here to view.
pSivida Corp. Announces Second Quarter Fiscal Year 2015 Financial Results...
WATERTOWN, Mass. pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results...
View ArticleClik here to view.
Life Sciences Hiring Index Posts Slight Decline to End Record Year
WEST ORANGE, N.J. ZRG Partners, Inc. has announced the final findings for 2014 with their fourth quarter Global Life Sciences Hiring Index. Despite a small drop from Q3, 2014 ended with the highest...
View ArticleClik here to view.
Acucela Received a Request to Hold a Special Meeting of Shareholders
SEATTLE Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening...
View ArticleClik here to view.
pSivida Announces U.S. Shipments of ILUVIEN® for DME to Start February 23
WATERTOWN, Mass. pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that initial nationwide...
View ArticleClik here to view.
Santen Chooses NTT Communications’ Hybrid-cloud ICT Infrastructure for Global...
TOKYO NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (NYSE:NTT), announced today that it has constructed an ICT backbone...
View ArticleClik here to view.
セカンド・サイトが2015年3月9日の第27回ROTH年次大会でプレゼンへ
米カリフォルニア州シルマー （ビジネスワイヤ） — 盲目の患者に視機能を提供する植え込み型視覚補綴物を開発・製造・販売するセカンド・サイト・メディカル・プロダクツ（NASDAQ:EYES）（「セカンド・サイト」または「当社」）は本日、社長兼最高経営責任者（CEO）のDr. Robert...
View ArticleClik here to view.
Second Sight将于2015年3月9日在ROTH第27届年会上呈报
加州SYLMAR (美国商业资讯) — Second Sight Medical Products, Inc. (NASDAQ:EYES) （”Second Sight”或”公司”）是为失明患者提供视觉功能的植入式视觉假体的开发者、制造商和营销商，该公司今天宣布，公司总裁兼首席执行官Robert Greenberg博士将在ROTH资本合伙人第27届年会上呈报，详情如下： 日期：...
View ArticleClik here to view.
Acucela to Hold 2015 Annual Meeting of Shareholders on June 8, 2015
SEATTLE Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of...
View ArticleClik here to view.
R-Tech Ueno: The End of a Phase 3 Clinical Study and Preliminary Findings...
TOKYO R-Tech Ueno (JASDAQ: 4573) announced today the end of a Phase 3 clinical study with Unoprostone (development code UF-021) ophthalmic solution that are being developed in our company for the...
View ArticleClik here to view.
Washington State Court Issues Order Requiring Acucela to Hold Special...
SEATTLE Acucela Inc. (TOKYO: 4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of...
View ArticleClik here to view.
Acucela Granted New Patent Covering Method of Use for Emixustat Hydrochloride
SEATTLE Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of...
View ArticleClik here to view.
pSivida Corp. Reports ILUVIEN® for DME Approved in Poland
WATERTOWN, Mass. pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the Office for...
View ArticleClik here to view.
Presbia Announces the Start of Commercialization of the Presbia Flexivue...
DUBLIN Presbia PLC (NASDAQ: LENS), an ophthalmic device company that has developed and is currently marketing Presbia Flexivue Microlens™, a proprietary optical lens implant for treating presbyopia,...
View ArticleClik here to view.
R-Tech Ueno: Announcement on Acquisition of the Right to Develop and...
TOKYO R-Tech Ueno (JASDAQ:4573) This is to announce that R-Tech Ueno, Ltd. (Head Office: Chiyoda-ku, Tokyo, CEO and President: Yukihiko Mashima, hereinafter referred to as “R-Tech Ueno”) has...
View ArticleClik here to view.
2015 Q1 Life Sciences Hiring Index Surges to All-Time High
WEST ORANGE, N.J. ZRG Partners has announced the findings for its first quarter Global Life Sciences Hiring Index from 2015. Lead by the Medical Device and Outsourcing/Services sectors, the first...
View ArticleClik here to view.
Ocata Therapeutics Announces Positive Results in Treating Macular...
MARLBOROUGH, Mass. Ocata Therapeutics, Inc. (“Ocata” or “the Company”; NASDAQ: OCAT), a leader in the field of Regenerative Ophthalmology™, announced that a study has been published that includes...
View Article